Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 4Completed 4Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Glioblastoma 9Central Nervous System Neoplasms 6Brain Neoplasms 6Oligodendroglioma 3Gliosarcoma 3Astrocytoma 3Sarcoma 2Optic Nerve Glioma 2Neoplasm Metastasis 2Glioma 2Ependymoma 2Zollinger-Ellison Syndrome 1Wilms Tumor 1Vipoma 1Unspecified Adult Solid Tumor, Protocol Specific 1Somatostatinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Retinoblastoma 1Recurrence 1Prolactinoma 1Pituitary Neoplasms 1Pheochromocytoma 1Ovarian Neoplasms 1Osteosarcoma 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Neuroectodermal Tumors 1Neuroblastoma 1Multiple Endocrine Neoplasia Type 2b 1

Interventions

plerixafor 1pazopanib 1lorukafusp alfa 1liposomal doxorubicin 1imetelstat 1Temozolomide 1Pentetic Acid 1Palliative Care 1Nutritional Support 1Minocycline 1MAGEA3 protein, human 1MAGEA1 protein, human 1Heparin 1Glutamine 1Gemcitabine 1GRN163L peptide 1Filgrastim 1Erlotinib Hydrochloride 1Electroacupuncture 1Docetaxel 1Dexamethasone 1Celecoxib 1Calcium Carbonate 1Analgesia 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Osteosarcoma × Temozolomide × Clear all
NCT02689336 2019-09-09

Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors

Washington University School of Medicine

Phase 2 Withdrawn
CNSGenitourinarySarcoma

Ependymoma, Glioma, Medulloblastoma, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡